Hemispherx Biopharma (HEB) Soars On Judgement Worth $1.40/Share, But Can They Collect
Tweet Send to a Friend
Hemispherx Biopharma, Inc. (NYSE: HEB) is up 30 percent in pre-open trading after announcing it was awarded a $188 million ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
